NSF International has acquired Pharmalytica Services, a pharmaceutical contract lab based in Connecticut. Pharmalytica provides a full range of GLP and GMP analytical services to the pharmaceutical and biotechnology industry from discovery support through commercialization, at its FDA-registered and DEA-licensed facility. Pharmalytica specializes in extractables and leachables testing, method development and validation, and bioanalysis.

NSF’s Health Sciences Division currently offers certification, training, consulting and GMP auditing for pharmaceuticals, dietary supplements and medical devices. As part of NSF’s Health Science Division, NSF Pharmalytica will provide analytical testing, consulting, training, registration, and R&D services. NSF Pharmalytica will operate primarily as a GLP & GMP contract lab, offering a wider array of independent testing and analytical services.

“Combining Pharmalytica’s knowledge in pharmaceutical analytical testing and R&D with our existing portfolio of dietary supplement and pharma solutions will help pharmaceutical companies worldwide make informed decisions when developing new products and strategies,” said Kevan P. Lawlor, NSF International’s chief executive officer and president.

“We have great confidence that Pharmalytica’s expertise, in synergy with NSF’s 65 years of testing and certification expertise, will be of great benefit in the development of new medicines worldwide,” said Dr. James Scull, executive director of Pharmalytica Services. Dr. Scull is a member of Contract Pharma’s Editorial Advisory Board.